MORPHOSYS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67 EUR | 0.00% |
|
+0.53% | +97.06% |
| May. 06 | MORPHOSYS : UBS reiterates its Neutral rating | ZD |
| Apr. 30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 2.72B | - | |||||
| 44.96B | - | |||||
| 42.65B | ||||||
| 41.85B | ||||||
| 29.04B | ||||||
| 26.08B |
- Stock Market
- Equities
- MOR Stock
- Charts MorphoSys AG
- Sector Chart
